Abstracts Archive - Page 1180 of 2607 - ACR Meeting Abstracts

Abstract Number: 659 • 2019 ACR/ARP Annual Meeting
Diminished Memory B-cells in Systemic Lupus Erythematosus Patients with Low Disease Activity
Sabine Zenz¹, Barbara Dreo ¹, Angelika Lackner ¹, Barbara Prietl ², Selina Kofler ², Harald Sourij ², Florentine Moazedi-Fuerst ¹, Monica D'Orazio ¹, Martin Stradner ¹, Winfried Graninger ¹ and Hans-Peter Brezinschek ¹, ¹Department of Internal Medicine/Division of Rheumatology and Immunology, Graz, Austria, ²2CBmed GmbH – Center for Biomarker Research in Medicine, Graz, Austria
Background/Purpose: B-cells play a pivotal role in the initiation and perpetuation of systemic lupus erythematosus (SLE). Recently, it has been demonstrated that in active SLE…
Abstract Number: 660 • 2019 ACR/ARP Annual Meeting
Antiphospholipid Syndrome (APS) in Systemic Lupus Erythematosus (SLE) Leads to a More Severe Disease
Leyre Riancho-Zarrabeitia¹, Víctor M Martinez-Taboada ², Iñigo Rua Figueroa ³, Fernando Alonso ⁴, María Galindo ⁵, Juan Ovalles-Bonilla ⁶, Alejandro Olivé-Marqués ⁷, Antonio Fernández-Nebro ⁸, Jaime Calvo-Alen ⁹, Raul Menor Almagro ¹⁰, Eva Tomero-Muriel ¹¹, Esther Uriarte Isacelaya ¹², Alina Boteanu ¹³, Mariano Andrés ¹⁴, Mercedes Freire González ¹⁵, Gregorio Santos Soler ¹⁶, Esther Ruiz Lucea ¹⁷, Monica Ibañez Barcelo ¹⁸, Ivan Castellvi ¹⁹, Carles Galisteo ²⁰, Víctor Quevedo Vila ²¹, Enrique Raya ²², Javier Narváez ²³, Lorena Expósito ²⁴, José A Hernández-Beriain ²⁵, Loreto Horcada Rubio ²⁶, Elena Aurrecoechea ²⁷ and Jose Maria Pego-Reigosa ²⁸, ¹Hospital Sierrallana, Torrelavega, Spain, ²Hospital Valdecilla, Santander, ³Hospital Doctor Negrin, Las Palmas, ⁴Unidad Investigación SER, Madrid, Spain, ⁵Hospital 12 De Octubre, Madrid, ⁶Hospital Gregorio Marañón, Madrid, Spain, ⁷Hospital German Trias i Pujol, Badalona, Spain, ⁸Hospital Carlos Haya, Malaga, Spain, ⁹Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ¹⁰Hospital Universitario de Jerez, Puerto De Santa María, Spain, ¹¹Hospital Universitario La Princesa, Madrid, Spain, ¹²Hospital Universitario Donosti, San Sebastian, Spain, ¹³Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁴Hospital General Universitario de Alicante, Alicante, Spain, ¹⁵Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹⁶Hospital Marina Baixa, Villajoyosa, Spain, ¹⁷Hospital Universitario Basurto, Bilbao, Spain, ¹⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ¹⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²⁰Hospital Parc Taulí, Barcelona, Catalonia, Spain, ²¹Hospital Comarcal Monforte, Monforteº, Spain, ²²Hospital Universitario Clínico San Cecilio, Granada, Spain, ²³Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ²⁴Hospital Universitario de Canarias, Las Palmas, Spain, ²⁵Hospital Insular Universitario de Gran Canaria, Las Palmas, Spain, ²⁶Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, ²⁷Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ²⁸Complexo Hospitalario Universitario, Vigo, Spain
Background/Purpose: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in SLE patients. Our aim was to investigate the differences between SLE…
Abstract Number: 661 • 2019 ACR/ARP Annual Meeting
Association of Serum and Urine Levels of TWEAK, MCP-1 and NGAL with Disease Activity in Systemic Lupus Erythematosus
SAFAK MIRIOGLU ¹, SUZAN CINAR ², Halil Yazici ³, Ahmet Gül ⁴, Lale Öcal ⁴, Murat Inanc ⁴ and Bahar Artim-Esen⁴, ¹Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, ISTANBUL, Turkey, ²Istanbul University,Department of Immunology, Institute of Experimental Medicine, ISTANBUL, Turkey, ³Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Nephrology, Istanbul, Turkey, ⁴Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: TWEAK, MCP-1 and NGAL, mediators in pathogenesis of systemic lupus erythematosus (SLE), are proinflammatory cytokines/chemokines that are thought as potential biomarkers reflecting disease activity.…
Abstract Number: 662 • 2019 ACR/ARP Annual Meeting
Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus
Brooke Williams¹, Bridget Muckian ¹, Claire Dykas ², Christine Peschken ³, Richard Furie ⁴, Elena Massarotti ⁵, Vanja sikirica ⁶, Steven Gilbert ⁷, Martin Hodge ⁷ and Peter Lipsky ⁸, ¹AMPEL BioSolutions, Charlottesville, VA, ²AmpelBioSolutions, Charlottesville, VA, ³University of Manitoba, Winnepeg, Canada, ⁴Northwell Health, Great Neck, NY, ⁵Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ⁶Pfizer, Boston, MA, ⁷Pfizer, Boston, ⁸AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Patient Reported Outcomes (PROs) can provide important data about the impact of a disease on an individual and/or the quality of the response to…
Abstract Number: 663 • 2019 ACR/ARP Annual Meeting
Peripheral Blood Toll Like Receptor 7 Expression and Serum Interferon Lambda 1 Levels in Systemic Lupus Erythematosus and Their Relation to Disease Activity and Lupus Nephritis
Hayam ElAggan¹, Nahla Farahat ¹, Mohamed Sakr ¹ and Shaymaa Tawfik ¹, ¹Faculty of Medicine, University of Alexandria, Alexandria, Egypt, Alexandria, Egypt
Background/Purpose: Toll-like receptor 7 (TLR7) can sense single-stranded RNA with subsequent induction of different interferon (IFN) types including IFN lambda (IFNL) and may contribute to…
Abstract Number: 664 • 2019 ACR/ARP Annual Meeting
Myxovirus Resistance Protein a Is a Useful Additional Histological Marker for Cutaneous Lupus Erythematosus
Wietske Lambers¹, Karina de Leeuw ², Femke Homan ¹, Berber Doornbos-van der Meer ¹, Hendrika Bootsma ³, Johanna Westra ² and Gilles Diercks ¹, ¹UMCG, Groningen, Netherlands, ²Dept. of Rheumatology and Clinical Immunology - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, ³University of Groningen, Groningen, Netherlands
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogeneous auto-inflammatory skin disease, that is driven to a great extent by interferon (IFN) type I1, and is…
Abstract Number: 665 • 2019 ACR/ARP Annual Meeting
Utility of Repeat Renal Biopsies in Patients with Lupus Nephritis in Western Australia
Warren Raymond¹, Alexandra Kang ², Daniel Wong ³, Aron Chakera ⁴ and Johannes Nossent ¹, ¹School of Medicine, The University of Western Australia, Crawley, Western Australia, Australia, ²PathWest, Nedlands, Western Australia, Australia, ³PathWest, Perth, Western Australia, Perth, Western Australia, Australia, ⁴Renal Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
Background/Purpose: The role of repeat renal biopsy (RRBx) in lupus nephritis (LN) to guide treatment or predict prognosis is not fully understood. We assessed the…
Abstract Number: 666 • 2019 ACR/ARP Annual Meeting
Sensitivity to Change of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort
William Fung¹, Mitra Moazzami ², Lisa Engel ³, Jiandong Su ⁴, Dennisse Bonilla ⁴, Pooneh Akhavan ⁵, Patricia Katz ⁶, Dorcas Beaton ⁷ and Zahi Touma ⁸, ¹University of Toronto, Toronto, ON, Canada, ²George Washington University, Washington, DC, ³University of Manitoba, Winnipeg, MB, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, Toronto, Canada, ⁶University of California, San Francisco, san francisco, CA, ⁷St. Michael's Hospital, Toronto, ON, Canada, ⁸University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Patient-reported outcomes (PROs) measures are a key component of the care of patients with systemic lupus erythematosus (SLE). The Patient Reported Outcomes Measurement Information…
Abstract Number: 667 • 2019 ACR/ARP Annual Meeting
The PROMIS-29 as a Measure of Type 1 and 2 SLE Activity
Nathaniel Harris¹, Amanda Eudy ², Megan Clowse ², Lisa Criscione-Schreiber ², Jayanth Doss ², Rebecca Sadun ², Jennifer Rogers ² and Kai Sun ², ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham
Background/Purpose: We have developed a new conceptual model that characterizes lupus into subtypes based on physician- and patient-reported measures: Type 1 is assessed by the…
Abstract Number: 668 • 2019 ACR/ARP Annual Meeting
Lack of Uptake of Prophylactic Human Papilloma Virus (HPV) Vaccination Among Women with Systemic Lupus Erythematosus (SLE) in the Detroit, MI Area, a High Risk Population
J. Patricia Dhar¹, Louis Saravolatz ² and Susan Szpunar ³, ¹Wayne State University, Bloomfield Hills, MI, ²Ascension St. John Hospital and Wayne State University, Grosse Pointe Woods, MI, ³Ascension St. John Hospital Hospital, Grosse Pointe Woods, MI
Background/Purpose: Women with SLE are at increased risk for cervical neoplasia likely because of infection with high risk (HR) HPV and thus should be considered…
Abstract Number: 669 • 2019 ACR/ARP Annual Meeting
Complement Activation in Probable Systemic Lupus Erythematosus (pSLE) May Predict Progression to SLE Defined by Fulfillment of ACR Classification Criteria
Rosalind Ramsey-Goldman¹, Roberta Alexander ², Sonali Narain ³, Cristina Arriens ⁴, Elena Massarotti ⁵, Daniel Wallace ⁶, Amit Saxena ⁷, Christopher Collins ⁸, Chaim Putterman ⁹, Kenneth Kalunian ¹⁰, Tyler O'Malley ¹¹, Armida Sace ², Rowena LaFon ², Jo-Anne Ligayon ², Claudia Ibarra ², John Conklin ², Thierry Dervieux ² and Arthur Weinstein ¹², ¹Northwestern University, Chicago, IL, ²Exagen, Vista, CA, ³Northwell Health, Great Neck, Long Island, NY, ⁴Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ⁶Cedars Sinai Medical Center/UCLA, Los Angeles, CA, ⁷New York University School of Medicine, New York, NY, ⁸MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ⁹Albert Einstein College of Medicine, New York, NY, ¹⁰Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ¹¹Exagen, Oceanside, CA, ¹²Georgetown University & Exagen, Inc, Claremont, CA
Background/Purpose: We reported (Ramsey-Goldman et al., Arthritis Rheumatol 2018: 70 [suppl 10]) that cell-bound complement activation products (CB-CAPs) and a multi-analyte assay panel with algorithm…
Abstract Number: 670 • 2019 ACR/ARP Annual Meeting
Association Between Ambient Air Pollutant Exposures and Childhood-Onset Systemic Lupus Erythematosus: A 12-Year Population-Based Cohort Study in Taiwan
Yenju Shih¹ and Chang-Ching Wei ², ¹Division of Immunology and Rheumatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Taichung city, Taiwan (Republic of China), ²Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, Children Hospital, China Medical University Hospital, Taichung, Taiwan, Taichung city, Taiwan (Republic of China)
Background/Purpose: Air pollutants exposure has been linked to inducing oxidative stress, pulmonary and systemic inflammation. We hypothesized that long-term exposure to air pollution would be…
Abstract Number: 671 • 2019 ACR/ARP Annual Meeting
Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
John G Hanly¹, Qiuju Li ², Li Su ³, Murray Urowitz ⁴, Caroline Gordon ⁵, Sang-Cheol Bae ⁶, Juanita Romero-Diaz ⁷, Jorge Sanchez-Guerrero ⁸, Sasha Bernatsky ⁹, Ann E Clarke ¹⁰, Daniel J Wallace ¹¹, David A Isenberg ¹², Anisur Rahman ¹³, Joan Merrill ¹⁴, Paul Fortin ¹⁵, Dafna Gladman ¹⁶, Ian Bruce ¹⁷, Michelle Petri ¹⁸, Ellen M Ginzler ¹⁹, MA Dooley ²⁰, Kristjan Steinsson ²¹, Rosalind Ramsey-Goldman ²², Asad A Zoma ²³, Susan Manzi ²⁴, Ola Nived ²⁵, Andreas Jönsen ²⁵, Munther A Khamashta ²⁶, Graciela Alarcón ²⁷, Elisabet Svenungsson ²⁸, Ronald F Van Vollenhoven ²⁹, Cynthia Aranow ³⁰, Meggan Mackay ³¹, Guillermo Ruiz-Irastorza ³², Manuel Ramos-Casals ³³, S Sam Lim ³⁴, Murat Inanc ³⁵, Kenneth C Kalunian ³⁶, Soren Jacobsen ³⁷, Christine Peschken ³⁸, Diane Kamen ³⁹, Anca Askanase ⁴⁰, Chris Theriault ¹ and Vernon Farewell ², ¹Dalhousie University, Halifax, NS, Canada, ²University of Cambridge, Cambridge, United Kingdom, ³Universidy of Cambridge, Cambridge, United Kingdom, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University of Birmingham, Birmingham, United Kingdom, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁷Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ⁸Toronto Western Hospital, Toronto, ON, Canada, ⁹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Cedars-Sinai Medical Centre, Beverly Hills, CA, ¹²Centre for Rheumatology, London, United Kingdom, ¹³University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, ¹⁵Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹⁶Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ¹⁷University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹State University of New York Downstate Medical Center, Brooklyn, NY, ²⁰UnC Kidney Centre, Chapel Hill, NC, ²¹Landspitali, University Hospital, Reykjavik, Iceland, ²²Northwestern University, Chicago, IL, ²³University of Glasgow, East Kilbride, United Kingdom, ²⁴Allegheny Health Network, Pittsburg, PA, ²⁵Lund University, Lund, Sweden, ²⁶King's College London School of Medicine, London, United Kingdom, ²⁷University of Alabama at Birmingham, Birmingham, ²⁸Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ²⁹Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ³⁰Feinstein Institute for Medical Research, Manhasset, NY, ³¹Feinstein Institute for Medical Research, New York, ³²Unidad de Enfermedades Autoinmunes, BioCruces Health Research Institute, Barakaldo, Spain, ³³Department of Autoimmune Diseases, ICMiD. Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX. Department of Medicine, University of Barcelona, Hospital Clínic, Barcelona, Spain., Barcelona, Spain, ³⁴Emory University, Atlanta, GA, ³⁵Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³⁶UC San Diego School of Medicine, LaJolla, CA, ³⁷Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ³⁸University of Manitoba, Winnipeg, Canada, ³⁹Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ⁴⁰Columbia University Medical Center, New York, NY
Background/Purpose: Although there is a large body of work on central nervous system (CNS) disease in SLE patients, involvement of the peripheral nervous system (PNS)…
Abstract Number: 672 • 2019 ACR/ARP Annual Meeting
Mouse SLE Studies Do Not Describe Human SLE
Ecem Sevim¹, Linjia Jia ², David Fernandez ³ and Michael Lockshin ⁴, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Mary Kirkland Center for Lupus Research, New York, NY, ⁴Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: Although mouse models of systemic lupus erythematosus (SLE) are useful proxies for human illness, they are heterogeneous, and publications about mouse SLE may not…
Abstract Number: 673 • 2019 ACR/ARP Annual Meeting
Clinical Characteristics of Lymphadenopathy in Systemic Lupus Erythematous: A Case Control Study from a Tertiary Care Center
Elizabeth Graef¹, Daniel Magliulo ¹, Norris Hollie ¹, Chelsea Marcus ² and Vasileios Kyttaris ³, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: While lymphadenopathy and/or lymphadenitis (LAD) is considered a relatively common clinical finding in SLE patients, its clinical significance is poorly understood. Previous studies described…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].